CN104721388B - The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe - Google Patents
The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe Download PDFInfo
- Publication number
- CN104721388B CN104721388B CN201410724450.5A CN201410724450A CN104721388B CN 104721388 B CN104721388 B CN 104721388B CN 201410724450 A CN201410724450 A CN 201410724450A CN 104721388 B CN104721388 B CN 104721388B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- influenza
- severe
- highest risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 206010022000 influenza Diseases 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 37
- 210000004072 lung Anatomy 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims 2
- 238000003748 differential diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 208000035143 Bacterial infection Diseases 0.000 abstract description 14
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 13
- 208000028399 Critical Illness Diseases 0.000 abstract description 9
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 20
- 230000003115 biocidal effect Effects 0.000 description 17
- 206010035664 Pneumonia Diseases 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 11
- 241000628997 Flos Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000801118 Lepidium Species 0.000 description 8
- 240000000249 Morus alba Species 0.000 description 8
- 235000008708 Morus alba Nutrition 0.000 description 8
- 240000001519 Verbena officinalis Species 0.000 description 8
- 235000018718 Verbena officinalis Nutrition 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000205585 Aquilegia canadensis Species 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 7
- 240000001745 Rheum palmatum Species 0.000 description 7
- 235000008090 Rheum palmatum Nutrition 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229940010454 licorice Drugs 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 241000218671 Ephedra Species 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 229910052602 gypsum Inorganic materials 0.000 description 6
- 239000010440 gypsum Substances 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 5
- 230000005180 public health Effects 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000021760 high fever Diseases 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000008779 ma-xing-shi-gan-tang Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
It is a kind of for treating the scorchingly hot Chinese medicine composition for closing pulmonary type of people at highest risk's influenza severe, which is characterized in that the bulk pharmaceutical chemicals of the Chinese medicine composition form and its weight ratio are as follows:
Description
Technical field: the present invention relates to Chinese medicine compositions and its preparation method and application, relate more specifically to a kind for the treatment of
People at highest risk's influenza severe is dialectical to belong to the scorchingly hot Chinese medicine composition and its preparation method and application for closing pulmonary type.
Background technique: influenza is the most common acute respiratory disease of the mankind, has become the great public health in the whole world at present and asks
Topic.Influenza parting include: A type, B-mode, the third type and other.According to the Ministry of Public Health's " influenza Clinics and Practices guide
(version in 2009,2011) " (2009,2011 years versions), influenza mild refers to upper respiratory tract influenza infection, and influenza severe is then hair
Lower respiratory tract infection caused by influenza virus i.e. pneumonia or bronchitis and pneumonia are given birth to.
Traditional Chinese medicine treatment influenza, that is, mild influenza has good curative effect, and traditional Chinese medicine treatment influenza, which has, brings down a fever and can change
The effect of kind patient's catarrh symptom has fully demonstrated in mild research.
Under modern medicine background, there are vaccine, advanced oxygen therapy, fast cooling, fluid infusion, antiviral, anti-bacterial drug etc.
Treatment means, thus the disease incidence of severe influenza is not high, case fatality rate is relatively low.However, severe influenza can make old-age group, child, pregnant
Woman and with occurring secondary infection after people at highest risk's illness of basic chronic diseases etc., and then become the cause of death.Secondary bacterial
The main reason for infection is influenza critical illness and is dead.
Influenza severe typically occurs in lower respiratory tract, and Bronchopneumonia is the most common, and serious pneumonia, acute respiratory distress are comprehensive
Simulator sickness is rare.It is respiratory failure, secondary bacterial infection, multiple organs failure that the cause of the death is common, need to suppress in time inflammatory development and after
Hair infection, to reduce the generation of critical illness, reduce case fatality rate.Flu victims whether secondary bacterial, fungal infection and the state of an illness it is light
Weight, the course of disease are positively correlated, and secondary infection causes dead probability to improve, and causing respiratory failure is underlying cause of death.High-risk people
After mass-sending raw influenza severe, it is easier to which secondary bacterial infection, sb.'s illness took a turn for the worse, and the death rate increases.
Traditional Chinese medicine treatment influenza has had many practice and trial, however how effectively to treat people at highest risk's influenza severe
It is still a problem in the prior art.The influenza severe suffered from for people at highest risk there is no to have the traditional Chinese medicine of definite curative effect at present
Treatment method.
Summary of the invention:
Due to the use of modern symptomatic drugs, Tamiflu, in terms of improving symptom, influenza nucleic acids yin,
The advantage of traditional Chinese medicine is unobvious or can not show by comparing, but advantage is prominent in terms of preventing and treating secondary bacterial infection, can be effective
Critical illness is reduced, case fatality rate is reduced.
It is a discovery of the invention that traditional Chinese medicine early stage participates in treatment disease of viral infection to prevention and treatment secondary bacterial, fungal infection, subtract
There is significant effectiveness using the type of antibiotic and dosage less, while helping to improve antibiotics sensitivity and antibiotic is avoided to bring
Adverse reaction, this is of great significance for the treatment and prognosis of severe flu victims, and especially antibiotic is indiscriminate in recent years
In the case where causing disaster.
Further, it is a discovery of the invention that traditional Chinese medicine treats people at highest risk's influenza severe, secondary bacterial infection can be reduced and resisted
The use of raw element, to reduce the generation of critical illness.
Further, it is a discovery of the invention that traditional Chinese medicine belongs to the scorchingly hot lung that closes for dialectical in people at highest risk's influenza severe
Situation, can be reduced the use of secondary bacterial infection and antibiotic, to reduce the generation of critical illness, have preferably treatment effect
Fruit.
People at highest risk's influenza severe refers to old-age group, child, pregnant woman and infects with the people at highest risk of basic chronic diseases etc.
Severe influenza.Meet severe criterion by the diagnostic criteria of influenza Clinics and Practices guide (version in 2011)
State of an illness distribution situation merges the most common of pneumonia, in experimental study of the invention, has 118 in 137 patients of institute's screening
Example pneumonic, the 86.13% of the total case load of Zhan；Secondly it to continue high fever, with violent cough, vomicas, bloody sputum or pectoralgia
There are 76 people, the 55.47% of the total case load of Zhan；Other severe performances are then relatively fewer.
The scorchingly hot progressive stage closed lung syndrome and be more common in influenza severe, clinical manifestation continue for high fever, and acutely, night is or not cough
It can fall asleep, no phlegm or few phlegm or blood-stained sputum, hemoptysis are out of strength, shortness of breath after activity, palpitaition, and tongue is red or cyanosis, moss thin yellow, veins string
Number, the more audibles of double lungs and bubble.The high intractable fever of this syndrome Phase patient, acutely cough becomes main suit, and rabat has already appeared leaching
Moisten shadow, oxygen saturation is normal or slightly declines.
The present invention relates to a kind of for treating the Chinese medicine composition and preparation method thereof of people at highest risk's influenza severe
And purposes, belong to the scorchingly hot Chinese medicine composition and its preparation method and application for closing pulmonary type in particular for dialectical in the disease.In this
The bulk pharmaceutical chemicals of drug composition form and its weight ratio are as follows:
Ephedra 3-10 gypsum 20-40 root bark of white mulberry 10-20 radix scutellariae 10-15
Lepidium seed 15-25 Verbena officinalis 20-40 honeysuckle 10-20 folium isatidis 5-15
Rheum palmatum (processed with wine) 2-10 honey-fried FLOS FARFARAE 5-15 grass river vehicle 10-20 licorice 2-10.
Preferably, the bulk pharmaceutical chemicals composition and its weight ratio of the Chinese medicine composition are as follows:
Ephedra 4-8 gypsum 25-35 root bark of white mulberry 12-18 radix scutellariae 8-12
Lepidium seed 18-23 Verbena officinalis 25-35 honeysuckle 12-18 folium isatidis 8-12
Rheum palmatum (processed with wine) 4-8 honey-fried FLOS FARFARAE 8-12 grass river vehicle 12-18 licorice 4-8.
It is highly preferred that the bulk pharmaceutical chemicals composition and its weight ratio of the Chinese medicine composition are as follows:
6 gypsum of ephedra, 30 root bark of white mulberry, 15 radix scutellariae 10
20 Verbena officinalis of lepidium seed, 30 honeysuckle, 15 folium isatidis 10
Careless 15 licorice 6 of river vehicle of 6 honey-fried FLOS FARFARAE of Rheum palmatum (processed with wine) 10.
Above-mentioned Chinese medicine composition can effectively treat people at highest risk's influenza severe, in particular for dialectical in the disease
Belong to the scorchingly hot person that closes pulmonary type.It can be effectively improved the symptom, sign, every clinical indices of influenza, reduce secondary bacterial infection, from
And the generation of critical illness is reduced, reduce the death rate.
Each bulk pharmaceutical chemicals in above-mentioned Chinese medicine composition are analyzed as follows:
Ephedra: latin name Herba Ephedrae, have inducing sweat and dispelling exogenous evils, relieving asthma sharp water the effect of.
Gypsum: there is clearing heat-fire, the effect that relieving restlessness is quenched the thirst.
The root bark of white mulberry: latin name Cortex Mori has the effect of removing heat from lung and relieving asthma, inducing diuresis for removing edema.
Radix scutellariae: latin name Radix Scutellariae, function heat-clearing and damp-drying drug, purging fire for removing toxin, arresting bleeding and miscarriage prevention.
Lepidium seed: latin name Semen Lepidii；Semen Descurainiae, function purging the lung of pathogenic fire sending down abnormally ascending, eliminating phlegm and relieving asthma,
Inducing diuresis for removing edema.
Verbena officinalis: latin name Herba Verbenae has clearing heat and detoxicating, promoting blood circulation to remove blood stasis, the effect of inducing diuresis for removing edema.
Honeysuckle: latin name Flos Lonicerae has the effect of clearing heat and detoxicating, wind-heat dissipating.
Folium isatidis: latin name Folium Isatidis plays the role of heat-clearing, removing toxic substances, cool blood.
Rheum palmatum (processed with wine): latin name Radix Et Rhizoma Rhei, discharge function is relatively slow, is apt to heat-clearing poison.
Honey-fried FLOS FARFARAE: latin name Flos Farfarae has moistening lung to lower qi, relieving cough and reducing sputum function.
Careless river vehicle: latin name Rhizoma Paridis also known as Paris polyphylla have the function of clearing heat and detoxicating.
Licorice: latin name Radix Glycyrrhizae invigorates the spleen and benefits qi, is clearing heat and detoxicating, expelling phlegm and arresting coughing, relieving spasm to stop pain
Effect.
The prescription analysis of above-mentioned Chinese medicine composition:
Chinese medicine thinks that influenza is wind-warm syndrome, and it is the first big method that it is clearing heat and detoxicating, which to treat warm disease, also referred to as gets rid of evils as First Essential, wherein
Poison with evil both cause of diseases comprising modern medicine also include pathologic, physiologic metabolism noxious products, pro-inflammatory cytokine etc., clearly
Hot class drug has both above-mentioned treatment needs.Antipyretic and antidotal type will have broad-spectrum antibacterial action, radix scutellariae, honeysuckle flower, mulberry in side more simultaneously
White skin, lepidium seed, Verbena officinalis, folium isatidis, careless river vehicle, Rheum palmatum (processed with wine) belong to such.
We done on the basis of the common prescription Ma Xing Shi Gan Tang of traditional treatment acute respiratory disease it is larger perfect,
In addition to honor Gu anticipate pharmacological property channel tropism, based on Ma Xing Shi Gan Tang, relieving the exterior syndrome with drugs pungent in flavor and cool in property heavy prescription, ventilating the lung and resolving phlegm relieving asthma just close lung governing skin and hair,
Department's breathing, influenza and grippe pneumonia are exactly " by attacking the lung first in temperature heresy " that lunar lung channel, lung lesion, the lung qi of initiation close strongly fragrant
Card the interpretation of the cause, onset and process of an illness.It is enhanced in conjunction with modern pharmacological research achievement and inhibits inflammation, promote to absorb, prevent and treat secondary bacterial infection, realized
Shorten the course of disease, reduce complication and the purpose of critical illness occurs.Easily become the machine of bacterium intrusion when respiratory mucosa damage
Meeting, so treatment is designed from anti-inflammatory, rush cell migration, improvement respiratory symptom.Clinic has been expanded compared with ancient prescription Ma Xing Shi Gan Tang
Disease range, improves curative effect by clinical test, has played the advantage of traditional Chinese medicine, lacks specific treatment (Ao Sita for influenza
The Wei optimum utility time is 36 hours), and current abuse of antibiotics and the case where therefore cause second of injury to patient,
Traditional Chinese medicine, which treats influenza and grippe pneumonia, has original value.
Chinese ephedra is monarch, effect is strong, effect extensively, have both heat-clearing, influenza A virus is inhibited, to Diplococcus pneumopniae,
Escherichia coli etc. have broad-spectrum antibacterial action.5 play cough-relieving with the root bark of white mulberry, lepidium seed, Verbena officinalis, honey-fried FLOS FARFARAE, licorice altogether, change
Phlegm is relievingd asthma, promoting the dispersing function of the lung qi-regulating function, and there are also aqueous vapors in purging the lung of pathogenic fire, is mitigated mucosal inflammation, oedema, is improved the effect of symptoms of pneumonia.
Further, the present invention also provides the methods for preparing above-mentioned Chinese medicine composition:
Chinese medicine composition in the present invention can be prepared using any method pharmaceutically received, it is preferable that be used
The method of decocting, for example, every dose of decocting is to 400 milliliters.Its instructions of taking is, 200 milliliters oral every time, twice a day；When necessary
2 doses can be taken daily, every 6 hours 1 time, every time 200 milliliters oral.It can also nasal feeding or colon instillation.
Further, the present invention also provides above-mentioned Chinese medicine composition preparation treatment it is scorchingly hot close pulmonary type people at highest risk stream
Row sexuality emits the purposes in the drug of severe.
Specific embodiment:
The preparation method of [embodiment 1] pharmaceutical composition
Prepare bulk pharmaceutical chemicals according to formula as below:
Ephedra 6g gypsum 30g root bark of white mulberry 15g radix scutellariae 10g
Lepidium seed 20g Verbena officinalis 30g honeysuckle 15g folium isatidis 10g
Rheum palmatum (processed with wine) 6g honey-fried FLOS FARFARAE 10g grass river vehicle 15g licorice 6g
Suitable quantity of water is added in above-mentioned raw materials medicine, boils by intense fire, continues to be cooked by slow fire 15 minutes, until medical fluid is 400ml, i.e.,
?.
The preparation method of [embodiment 2] pharmaceutical composition
Prepare bulk pharmaceutical chemicals according to formula as below:
Ephedra 3g gypsum 20g root bark of white mulberry 20g radix scutellariae 15g
Lepidium seed 15g Verbena officinalis 40g honeysuckle 10g folium isatidis 15g
Rheum palmatum (processed with wine) 3g honey-fried FLOS FARFARAE 18g grass river vehicle 20g licorice 2g
Suitable quantity of water is added in above-mentioned raw materials medicine, boils by intense fire, continues to be cooked by slow fire 15 minutes, until medical fluid is 400ml, i.e.,
?.
[embodiment 3] clinical experimental study
Research purpose: it evaluates the clinical of traditional Chinese medicine composition for treating influenza people at highest risk's severe of the present invention and treats
Effect is reducing the effect in the generation of people at highest risk's complication.
1, object and method
1.1 case sources and grouping
In November, 2012 to during in April, 2013 in the medical of Beijing-Tianjin Shen Yuelu Gan Deng Di Shiwujia Grade III Class A hospital
People at highest risk's severe flu victims (Flu-A/influenza B) were fallen ill within 48 hours, and age, men and women, basis disease are not
Limit.It excludes pregnant woman and basis disease needs special monitoring and therapeutic person.Patient is included in the combination of Chinese tradiational and Western medicine respectively with center random device
Treatment group and simple western modern medicine treatment group, hereinafter referred to as Chinese and Western group, doctor trained in Western medicine group.
The screening that this research institute has patient all to carry out influenza virus A type Yu B-mode versatility, with regard to the case of FAS collection
For final result, in 137 patients, Flu-A always sifts out 30, accounts for the 21.90% of total number of persons, and influenza B screening goes out 47
Example accounts for the 34.31% of sum.Influenza nucleic acid positive patient is 56.21% in total.
The quick detection case of severe flu victims influenza virus
| Chinese and Western group | Doctor trained in Western medicine group | Total number of cases | Account for case percentage (N=137) | |
| Flu-A | 13 | 17 | 30 | 21.90% |
| Influenza B | 26 | 21 | 47 | 34.31% |
| It is total | 39 | 38 | 77 | 56.21% |
Note: wherein Chinese and Western group and doctor trained in Western medicine group each 1 double positives
1.2 diagnosis and treatment foundation and observational study method
1.2.1 diagnosis and therapeutic scheme
Western medical treatment in doctor trained in Western medicine group and Chinese and Western group with the Ministry of Public Health " influenza Clinics and Practices guide (2009,
Version in 2011) " (general office, the Ministry of Public Health is about printing and distributing the logical of " Influenza A H1N1 diagnosis and treatment scheme (the trial version second edition in 2009) "
Know 2009 Nian Qiyue, general office, Ministry of Public Health file, about printing and distributing " influenza Clinics and Practices guide (2011 years
Version) " notice, defend and do doctor's political affairs and send out (2011) No. 25) for foundation.The traditional Chinese medicine treatment of Chinese and Western group uses the embodiment of the present invention 1 or 2
Prepared Chinese medicine composition, daily 1-2 agent.
1.2.2 laboratory checks
The quick Pathogen test colloidal gold immunity chromatography of first, influenza B virus, qualitative detection people's nasopharyngeal secretions mark
Influenza nucleoprotein antigen in this.Kit inspires confidence in Biotechnology Co., Ltd by Guangzhou ten thousand and provides, unified to configure.All sights
It examines object and carries out vital sign monitoring after being admitted to hospital, do blood routine, hepatic and renal function, partially do chest x mating plate or chest CT, portion
Point case does the detection such as blood gas analysis, T cell subgroup.Main abnormal index is checked.
1.2.3 clinical symptoms and sign
Selected case has a high fever, acutely cough, the symptoms such as tired out of strength, and tongue is red or cyanosis, wiry and frequent pulse, double more audibles of lung
And bubble, rabat have already appeared infiltration shadow, oxygen saturation is normal or slightly declines, and meets the scorchingly hot TCM syndrome for closing lung card type
Performance
1.2.4 observed content
The incidence of patient records its clinical manifestation during being hospitalized daily, carries out investigation records to vital sign.Mainly
Final result index is the service condition of case fatality rate, fever time, secondary bacterial infection, glucocorticoid, antibiotic.Clinical recovery mark
Standard is body temperature normal 3 days, and the detection of throat swab influenza nucleic acids is negative, and rabat or chest CT examination prompt pneumonia are inhaled substantially
It receives, observes the period 7-14 days.The safety of therapeutic agent is recorded simultaneously, adverse events and giving are analyzed.
1.3 statistical method
Institute of Basic Research in Clinical Medicine, Chinese Academy of Chinese Medical Sciences undertakes Database, center stochastic system, data
Statistics.Statistical data is to enter group and enter after group the 3rd, 6,14 day for principal statistical point.P value, which will be less than or equal to 0.05, to be considered
The difference examined has statistical significance, if the difference that P value will be considered examining greater than 0.05 is not statistically significant；Measurement data is adopted
It is compared with t inspection, enumeration data carries out comparison among groups using card side, correction card side, rank sum test.Engage simultaneous in Beijing
Third-party intendance Quality Control is done by ancient cooking vessel Pharmaceutical Technology Co., Ltd.
2, result
2.1 demographic data
Multicenter is included in 137 patients, male 73, female 64 altogether；Minimal ages 1 years old, max age 96 years old, wherein 5 years old
And following children totally 59 people, account for 60.58%.Chinese and Western combines group 69, doctor trained in Western medicine group 68.
Demographic data's (gender, age, height, weight), vital signs (body temperature, blood pressure, the heart when entering group to patient
Rate, respiratory rate, pulse), disease information (medical history, high risk factor, aetology) no significant difference for statistical analysis (is shown in Table
1)。
Table 1, two group of age (year), gender, cause of disease compare no significant difference
2.2 clinical symptoms and sign baseline case
Pneumonia, fever, cough, amount of expectoration, headache, arthralgia, DOMS, foul wind between Chinese and Western group and doctor trained in Western medicine group when entering group
It trembles with fear, shiver, perspiring, the equal no difference of science of statistics of the multinomial evaluation index of symptoms such as sneeze, nasal congestion, pharyngalgia.Baseline physiology between group
Pathological index there are no significant difference (being shown in Table 2).
Body temperature when table 2, baseline, breathing, heart rate, cough comparison without significant difference
Efficacy analysis after 2.3 treatments
Combination of Chinese tradiational and Western medicine group enters group 3 days without death, 1 93 years old old man (006008) of doctor trained in Western medicine group, and sb.'s illness took a turn for the worse, and family members abandon
The automatic discharge for the treatment of, the death in the 4th day after discharge.Admission days are more without significant difference.Front and back itself is right in treatment group
Impinge upon bring down a fever, alleviate acutely cough, syndrome characterized by dyspnea improves etc. that there were significant differences (being shown in Table 3), but comparison among groups are without significant difference.
Fever time (day), syndrome characterized by dyspnea, cough improve without significant difference for the first time for table 3, comparison among groups
The service condition of 2.4 pneumonia and antibiotic
The main reason for secondary bacterial infection is influenza critical illness and is dead easily becomes thin when respiratory mucosa damage
The chance of bacterium intrusion, clinical common antibiotics prevention or treatment.Two groups of diagnosis of pneumonia and record inflammation integrals when entering group
It is not 48,52, inflammation integrates comparison among groups without significant difference.Two groups have about 1/3 patient to use a kind of antibiotic, mainly
Effect is prevention bacterium infection.The case load of two kinds and two or more antibiotic is used for that must treat secondary bacterial infection,
Doctor trained in Western medicine group is significantly more than traditional Chinese and western medicine group, and has 2 generation mycotic infections in doctor trained in Western medicine group, while having used antifungal.Two groups
There is significant difference (being shown in Table 4) in the comparison using antibiotic and its in terms of combining the number of cortex hormone of aadrenaline, type.
Table 4, two groups of pneumonia two kinds and the above medicining condition
Table 5, Chinese and Western group and doctor trained in Western medicine group use Antibiotics list
Documented antibiotic is the drug of clinically used treatment pulmonary bacterial, the sense according to patient in table 5
The bacterial species and severity of dye are selected, and dosage is within routine clinical amount ranges.Table 5 shows there is 5 in the group of Chinese and Western
Example case must treat secondary bacterial infection and use two kinds and two or more antibiotic, have 11 cases that must control in doctor trained in Western medicine group
It treats secondary bacterial infection and uses two kinds and two or more antibiotic, and the rank and effect of antibiotic used in the race of Chinese and Western
Majority is lower than antibiotic selected by doctor trained in Western medicine group, statistical analysis, and difference P < 0.05 between two groups has the significant meaning of statistics.
The data result shows that present invention Chinese medicine composition claimed can effectively mitigate the Pulmonary bacterial of influenza patient with severe symptoms
Infection improves patient's prognosis, reduces the death rate of high Cavity in Critical Patients to reduce the use of antibiotic.
2.5 in terms of the Enzyme target of the inflammation such as mark cardiac muscle, lung, are significantly improved in pretherapy and post-treatment group, comparison among groups
Without significant difference.
2.6 safety indexes blood routines, routine urinalysis, hepatic and renal function do not find the exception that treatment causes.When treatment end
Safety analysis, which is shown, does not find adverse events, does not find adverse reaction relevant to Chinese medicine composition of the invention is used.
3, brief summary
3.1 researchs are multicenter, Randomized controlled clinical study, are included in 137 people at highest risk's severe influenzas of FAS manifold, 5
Year old or less account for about 60.58% based on children.Patient is divided into traditional Chinese and western medicine group and doctor trained in Western medicine group, and two groups enter group base line level in population
The various aspects such as natural data, aetology, the state of an illness, symptom, physico-chemical examination have fine homogeneity, and items check data through statistics
Processing is without significant difference.
3.2 when entering i.e. the course of disease the 7-8 days the 6th day of group treatment progress, and various symptoms sign all significantly improves, before treatment
There were significant differences afterwards, comparison among groups therapeutic equivalence, no significant difference.Without death, doctor trained in Western medicine group example 93 during two groups of treatments
Year, patient was admitted to hospital 3 days, and sb.'s illness took a turn for the worse abandons treating, the death in the 4th day after discharge, is considered as treatment and turns grave illness example in vain.
The influence of 3.3 pairs of state of an illness, which is shown in, to be prevented, treated viral pneumonia secondary bacterial and mycotic infection, reduces antibiotic
Use aspect played preferable effect, combination of Chinese tradiational and Western medicine group is significantly better than simple western medical treatment group.
3.4 research institutes are safe with drug.Chinese medicine composition decoction does not cause adverse events.Related peace before and after treatment
It is showed no and changes with drug-associated all referring to mark blood routine, Liver and kidney function.
4, conclusion
This research object is people at highest risk's influenza severe cases 137, and child is in the majority, is gone to a doctor in 48 hours.Traditional Chinese medicine is early
Phase intervention severe treatment of influenza can efficiently reduce the use of secondary bacterial infection and antibiotic.
Bibliography Gao Xuemin edits first edition Chinese pharmacology People's Health Publisher in November, 2000.
Claims (9)
1. a kind of belong to the scorchingly hot Chinese medicine composition for closing pulmonary type for treating people at highest risk's influenza severe differential diagnosis in tcm, special
Sign is that the bulk pharmaceutical chemicals of the Chinese medicine composition form and its weight ratio are as follows:
2. Chinese medicine composition described in claim 1, which is characterized in that the bulk pharmaceutical chemicals of the Chinese medicine composition form and its weight ratio
Example are as follows:
3. Chinese medicine composition of any of claims 1 or 2, which is characterized in that the bulk pharmaceutical chemicals of the Chinese medicine composition form and its again
Amount ratio are as follows:
4. Chinese medicine composition of any of claims 1 or 2, which is characterized in that be made into pharmaceutically acceptable dosage form.
5. Chinese medicine composition as claimed in claim 3, which is characterized in that be made into pharmaceutically acceptable dosage form.
6. the preparation method of Chinese medicine composition as claimed in claim 1 or 2, it is characterised in that: add water to cook.
7. the preparation method of Chinese medicine composition described in claim 3, it is characterised in that: add water to cook.
8. Chinese medicine composition as claimed in claim 1 or 2 is scorchingly hot in preparation treatment people at highest risk's influenza severe Chinese medical discrimination
Close the purposes in the drug of lung card.
9. Chinese medicine composition as claimed in claim 3, which belongs to scorchingly hot in preparation people at highest risk's influenza severe Chinese medical discrimination, closes lung
Purposes in the drug of card.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410724450.5A CN104721388B (en) | 2014-12-02 | 2014-12-02 | The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410724450.5A CN104721388B (en) | 2014-12-02 | 2014-12-02 | The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104721388A CN104721388A (en) | 2015-06-24 |
| CN104721388B true CN104721388B (en) | 2019-04-05 |
Family
ID=53446184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410724450.5A Expired - Fee Related CN104721388B (en) | 2014-12-02 | 2014-12-02 | The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721388B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184886B (en) * | 2017-05-16 | 2018-06-19 | 贾洪章 | Anti virus herb composition and its preparation method and application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733110A (en) * | 2005-08-12 | 2006-02-15 | 山东鲁泰环中制药有限公司 | Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparing the same |
| CN1943655A (en) * | 2005-10-08 | 2007-04-11 | 周小明 | A Chinese traditional medicinal composition for treatment of the light outbreak during acute attack of the infant bronchial asthma and its preparing method |
| CN1977912A (en) * | 2006-12-14 | 2007-06-13 | 尹立新 | Chinese medicinal composition for treating cold |
| CN101143176A (en) * | 2007-08-25 | 2008-03-19 | 尹克华 | Traditional Chinese medicine for treating pneumonia |
| CN101549060A (en) * | 2008-04-01 | 2009-10-07 | 河北以岭医药研究院有限公司 | Medicament containing gnetales for treating bronchitis and preparation method thereof |
| CN102293912A (en) * | 2011-09-28 | 2011-12-28 | 曹文真 | Chinese medicine for treating pneumonia |
| CN102716223A (en) * | 2012-06-27 | 2012-10-10 | 巫军 | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof |
| CN103599287A (en) * | 2013-08-17 | 2014-02-26 | 郝振荣 | Effective prescription for treating excessive-heating asthma |
-
2014
- 2014-12-02 CN CN201410724450.5A patent/CN104721388B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733110A (en) * | 2005-08-12 | 2006-02-15 | 山东鲁泰环中制药有限公司 | Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparing the same |
| CN1943655A (en) * | 2005-10-08 | 2007-04-11 | 周小明 | A Chinese traditional medicinal composition for treatment of the light outbreak during acute attack of the infant bronchial asthma and its preparing method |
| CN1977912A (en) * | 2006-12-14 | 2007-06-13 | 尹立新 | Chinese medicinal composition for treating cold |
| CN101143176A (en) * | 2007-08-25 | 2008-03-19 | 尹克华 | Traditional Chinese medicine for treating pneumonia |
| CN101549060A (en) * | 2008-04-01 | 2009-10-07 | 河北以岭医药研究院有限公司 | Medicament containing gnetales for treating bronchitis and preparation method thereof |
| CN102293912A (en) * | 2011-09-28 | 2011-12-28 | 曹文真 | Chinese medicine for treating pneumonia |
| CN102716223A (en) * | 2012-06-27 | 2012-10-10 | 巫军 | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof |
| CN103599287A (en) * | 2013-08-17 | 2014-02-26 | 郝振荣 | Effective prescription for treating excessive-heating asthma |
Non-Patent Citations (2)
| Title |
|---|
| 清热解毒液保留灌肠治疗急性感染性疾病240例;赖善中等;《中国中医急症》;20070315(第03期);354-355 * |
| 重用石膏为主方剂治疗小儿高热75例;黄钟燕;《广西中医药》;19961020(第05期);15-16 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104721388A (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940832B (en) | Medicament for treating chronic bronchitis and preparation method thereof | |
| CN111298048B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN105233231A (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN117137998B (en) | Pharmaceutical composition for treating yin deficiency damp-heat type viral infection and pulmonary nodule, preparation and application thereof | |
| CN104721388B (en) | The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe | |
| CN104208473A (en) | Traditional Chinese medicine composition for treating wind-heat type cough and asthma and use thereof | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN102920933B (en) | Chinese medicinal preparation for treating chronic obstructive pulmonary diseases | |
| CN102772525B (en) | Traditional Chinese medicine for wind-heat type acute bronchitis | |
| CN104958419A (en) | Roxburgh anoectochilus terminal bud heat-clearing and detoxifying capsule and production process thereof | |
| CN102205037B (en) | Oral medicinal composition for treating infantile bronchitis caused by bacterial infection and preparation method thereof | |
| CN103463401B (en) | Asthma medicine for infants | |
| CN104587017B (en) | A kind of Clearing heat and removing obstruction of fu-organs, pharmaceutical composition of the promoting flow of qi and blood circulation and its production and use | |
| CN103110910B (en) | Agent for treating acute upper respiratory infection | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof | |
| CN114732887B (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN116407597B (en) | Xuan Bai pulse-activating decoction for resisting coronavirus and preparation method thereof | |
| CN102423337A (en) | Chinese medicinal composition for treating allergic rhinitis and application of Chinese medicinal composition | |
| CN114732889B (en) | Traditional Chinese medicine composition and traditional Chinese medicine oral preparation for treating phlegm turbidity and lung obstruction in acute attack stage of bronchial asthma | |
| CN108926672B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN105902943A (en) | Medicine composition for treating wind heat cough of children | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma | |
| Wang et al. | Research Progress on Recognition and Treatment of RSV Infection in Traditional Chinese Medicine | |
| CN102908594B (en) | Anti-influenza and anti-common-cold Chinese herbal compound prescription and preparation method and application thereof | |
| CN102764347A (en) | Medicament for treating cold and complications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200107 Address after: 100015 Beijing City, Chaoyang District Shun Street No. 8 Patentee after: BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSITY Address before: 100015 Beijing City, Chaoyang District Shun Street No. 8 Co-patentee before: Wang Rongbing Patentee before: BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSITY |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190405 |